✦ LIBER ✦

Cancer Immune Therapy || Immunotoxins and Recombinant Immunotoxins in Cancer Therapy

✍ Scribed by Stuhler, Gernot; Walden, Peter

Publisher: Wiley
Year: 2002
Tongue: German
Weight: 581 KB
Volume: 10.1002/3527600795
Category: Article
ISBN: 3527600795
DOI: 10.1002/3527600795.ch17

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer Immune Therapy || Immunosuppresiv

Cancer Immune Therapy || Immunosuppresive Factors in Cancer

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 258 KB 👁 2 views

Cancer Immune Therapy || Interleukinâ1

Cancer Immune Therapy || Interleukinâ10 in Cancer Immunity

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 174 KB 👁 1 views

Cancer Immune Therapy || T Cells in Tumo

Cancer Immune Therapy || T Cells in Tumor Immunity

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 163 KB 👁 2 views

Cancer Immune Therapy || Dendritic Cells

Cancer Immune Therapy || Dendritic Cells and Cancer: Prospects for Cancer Vaccination

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 279 KB 👁 2 views

Cancer Immune Therapy || Immune Cells in

Cancer Immune Therapy || Immune Cells in the Tumor Microenvironment

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 494 KB 👁 2 views

Recombinant polyclonal antibodies for ca

Recombinant polyclonal antibodies for cancer therapy

✍ Jacqueline Sharon; Meredith A. Liebman; Brent R. Williams 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

## Abstract Although monoclonal antibodies are increasingly used for cancer therapy, remissions are only temporary due to emergence of tumor cell escape variants that are no longer affected by the antibody. The emergence of escape variants could be minimized by multi‐targeting of tumor cells with p